FORM PTO-1083

Docket No.: 478.1080 Date: July 14, 2006

Mail Stop: Amendment

COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, VA 22313-1450

In re application of:

David MORTON, et al.

Serial No.:

10/571,884 ~

Filed:

March 13, 2006

For:

DRY POWDER COMPOSITION COMPRISING A BENZODIAZEPINE FOR PULMONARY

INHALATION

Sir:

Transmitted herewith is a Supplemental Information Disclosure Statement Under 37 CFR § 1.56 (2 pages) in the above-identified application.

[] [] [X]	Applio No fe	Small entity status under 37 C.F.R. 1.9 and 1.27 has been previously established. Applicants assert small entity status under 37 C.F.R. 1.9 and 1.27. No fee for additional claims is required. A filing fee for additional claims calculated as shown below, is required:									
[X]	[]Pe	transmitted herewith are: etition for month extension under 37 C.F.R. 1.136									
	[X] C	other: Form PTO 1449 (1 page); Appendix A.									
[]	Check(s) in the amount of \$0.00 is/are attached to cover:										
		[] Filing fee for additional claims under 37 C.F.R. 1.16									
	[]Pe	etition for month extension under 37 C.F.R. 1.136									
	[]01	her:									
[X]	The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0552.										
	[X]	Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by check submitted herewith.									
	[X]	Any patent application processing fees under 37 C.F.R. 1.17.									
	[X]	Any patent application processing fees under 37 C.F.R. 1.17. Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, and									

it is hereby requested that this be a petition for an automatic extension of the under 37 CFR 1.136.

Cary S. Kappel, Reg. No. 36,561

DAVIDSON, DAVIDSON & KAPPEL, LLC

485 Seventh Averque, 14th Floor New York, New York 10018

Tel: (212) 736-1940 Fax: (212) 736-2427

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with sufficient postage to the United States Postal Service as "first class mail" in an envelope addressed to "Mail Stop: Amendment; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" on July 14, 2006. DAVIDSON, DAVIDSON & KAPPEL, LLC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

David MORTON et al.

Serial No.:

10/571,884

Filed:

March 13, 2006

For:

DRY POWDER COMPOSITION COMPRISING A

BENZODIAZEPINE FOR PULMONARY

INHALATION

Mail Stop: Amendment Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

July 14, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56

Sir:

In accordance with the provisions of 37 C.F.R. § 1.97, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449 (1 sheet) for consideration by the Examiner in connection with the examination of the above-identified patent application.

Applicants also respectfully advise the Examiner of the following co-pending U.S. patent applications and a granted patent, all of which are commonly assigned to the owners of the instant application:

- U.S. Patent Application Serial No. 10/570,902, "Methods for Preparing Pharmaceutical Compositions," filed March 7, 2006;
- U.S. Patent Application Serial No. 10/552,326, "Devices and Pharmaceutical Compositions for Enhancing Dosing Efficiency," filed March 20, 2006; and

478.1080

U.S. Patent Application Serial No. 10/571,146, "Dry Powder Composition Comprising

Co-jet Milled Particles for Pulmonary Inhalation," filed March 9, 2006.

Pursuant to 37 C.F.R. § 1.98 (a)(2)(iii), the Examiner's attention is directed to Appendix

A, attached hereto, which contains the following:

1) Specification and pending claims of U.S. Patent Application Serial No. 10/570,902;

2) Specification and pending claims of U.S. Patent Application Serial No. 10/552,326;

and

3) Specification and pending claims of U.S. Patent Application Serial No. 10/571,146.

It is respectfully requested that the references cited in the accompanying Form PTO-1449

(1 sheet) be considered and made of record.

The present Information Disclosure Statement is filed under 37 C.F.R. §1.97(b), before

the mailing of a first Office Action on the merits. Accordingly, it is believed that no fee is due.

However, if it is determined that any fee is due, the Examiner is authorized to charge said fee to

Attorney Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, PAVIDSON & KAPPEL, LLC

By:

Cary S. Kappel

Reg. No. 36,561

DAVIDSON, DAVIDSON & KAPPEL, LLC

485 Seventh Avenue, 14th Floor

New York, NY 10018

(212) 736-1940

2

JUL 1 7 2006 RS

FORM PTO-1449 (REV. 7-80)

EXAMINER

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 478.1080

SERIAL NO.: 10/571,884

LIST OF PRIOR ART CITED BY APPLICANT

APPLICANT(S): David MORTON et al.

(Use several sheets if necessary)														
										FILING DATE: Marc	h 13, 2006	GROUP:	GROUP:	
								U.	S. PATENT DO	CUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DAT	
	AA	6	4	7	5	5	2	3	11/05/02	Staniforth	424	070.100		,
	AB	20	05	01	52	8	4	9	07/14/05	Staniforth	424	489		
	AC	20	03	01	85	7	6	4	10/02/03	Staniforth et al.	424	045		
	AD	20	03_	01	75	2	1	4	09/18/03	Staniforth et al.	424	045		
	AE	20	03	01	65	4	3	6	09/04/03	Staniforth et al.	424	045		
	AF	20	03	01	62	8_	3	5	08/28/03	Staniforth et al.	424	046		
	AG	20	04	00	37	7	8	5	02/26/04	Staniforth et al.	424	046		
	AH	20	04	00	71	6	3	5	04/15/04	Staniforth et al.	424	046		
	Al	20	04	00	47	8	1	0	03/11/04	Staniforth et al.	424	046		
	AJ													
	AK						<u> </u>	ļ						
	AL			<u> </u>										
	AM													
	AN						<u></u>					<u> </u>		
	AO						<u> </u>							
	AP												<u> </u>	
							···	FOR	EIGN PATENT I	DOCUMENTS				<u>. </u>
	DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	AQ													
		,			01	THER P	RIOR	ART (In	cluding Author,	Title, Date, Pertinent Pag	ges, Etc.)			
	AR	<u> </u>												

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED